Psychedelics, Pelvic Pain, and the Neurocentric Future of Endometriosis Care

An ESSI commentary on chronic pelvic pain, neuropathic pain, fibromyalgia, central sensitization, and why the vagus nerve is now entering the conversation.

Bottom line: Psychedelic medicine is suddenly newsworthy again, but it is not an approved treatment for endometriosis pain. The real story is that the field is beginning to take seriously a neurocentric model of chronic pelvic pain – one that includes central sensitization, neuropathic pain, fibromyalgia-like overlap, and possibly the autonomic nervous system, including the vagus nerve.

The Policy News That Changed the Tone

On April 18, 2026, the Trump administration announced an executive-order-driven push to accelerate psychedelic medicine research and regulatory review, with particular attention to ibogaine and serious mental illness. That does not mean psychedelic drugs are now proven or approved for chronic pelvic pain. However, it does mean the federal climate has shifted enough that the conversation has moved from cultural fringe to serious translational medicine.

Why This Matters in Endometriosis

Endometriosis has long been misunderstood as a disease that can be explained by visible lesions alone. At ESSI, we have argued for a more neurocentric view: some patients have nociceptive pain from active disease, some have neuropathic pain from nerve irritation or postsurgical injury, and many develop central sensitization or nociplastic pain in which the nervous system itself becomes hyper-reactive.

This helps explain why some patients continue to suffer even when imaging is incomplete, pathology is subtle, or prior surgery has already been performed.

The Neurocentric Model

A neurocentric framework does not minimize disease; it expands it. It recognizes that endometriosis can trigger a cascade involving peripheral nerves, spinal amplification, pain memory, pelvic floor guarding, cross-organ sensitization, autonomic dysregulation, mood symptoms, sleep disruption, and fibromyalgia-like widespread pain.

In practical terms, this means an expert pelvic pain program cannot stop at anatomy. It has to understand nerve pathways, brain-body signaling, overlapping pain syndromes, and the biological consequences of prolonged pain exposure.

Why Psychedelics Are Suddenly Interesting

Psychedelic-assisted therapy is intriguing not because it behaves like a traditional painkiller, but because it may alter pain salience, fear conditioning, rigid network activity, and the emotional amplification that often locks chronic pain into place.

That hypothesis has made the field especially interested in chronic pain states with a large central component, including neuropathic pain, fibromyalgia, and persistent pain after the original trigger has evolved or partially resolved. For endometriosis specialists, that is exactly the edge of the question: could some patients with chronic pelvic pain eventually benefit from therapies that target the nervous system’s pain processing rather than lesions alone?

What the Evidence Actually Shows

The evidence remains early, and there is no high-quality published trial proving that psychedelics treat endometriosis-related chronic pelvic pain. The strongest human signals so far come from other conditions.

• A 2025 open-label pilot study of psilocybin-assisted therapy in adults with fibromyalgia suggested the treatment was generally well tolerated and that some participants reported improvement in pain severity, pain interference, anxiety, sleep, and global symptom burden.

• While encouraging, this data is still preliminary and far from practice-changing.

• For chronic pelvic pain, the field is even earlier: a pilot feasibility study of psilocybin in women with chronic pelvic pain is only now emerging.

That tells us the question is legitimate – and also that the answer is not here yet.

Neuropathic Pain, Fibromyalgia, and the ESSI Patient

This matters because many patients referred to tertiary endometriosis centers do not fit into a purely mechanical pain model.

• Some have burning pelvic pain, vulvar pain, rectal pain, abdominal wall pain, dyspareunia with allodynia, bladder pain, bowel urgency, or radiating leg pain that behaves like neuropathic disease.

• Others have overlapping fatigue, cognitive fog, widespread tenderness, headaches, IBS, or sleep disruption that resemble fibromyalgia or broader nociplastic pain states.

These are exactly the patients for whom a neurocentric approach becomes indispensable.

Now Add the Vagus Nerve

The vagus nerve is becoming more interesting in chronic pain because it sits at the intersection of autonomic regulation, inflammation, affective state, gut signaling, and brain-body communication. Research in other fields suggests vagal pathways may influence inflammatory tone, visceral sensitivity, stress reactivity, and central pain processing.

In endometriosis, this is tantalizing because many patients exhibit a mixed phenotype: pelvic pain, GI dysregulation, anxiety amplification, poor sleep, fatigue, and autonomic symptoms. That does not prove a vagus-nerve treatment for endometriosis, but it strengthens the idea that pelvic pain should be studied as a network disorder, not merely as isolated pelvic pathology.

What Not to Do

This is where medicine has to stay disciplined. Psychedelics should not be used as a fashionable way to psychologize endometriosis or to distract from the importance of expert diagnosis, excisional surgery when indicated, treatment of adenomyosis, evaluation of neuropathic generators, pelvic floor therapy, or the management of associated conditions.

Regulatory acceleration is not the same as scientific proof. Psychedelic therapies are not benign wellness products; they carry psychological risks and, in some cases, cardiovascular concerns.

What the Future May Look Like

ESSI view: The future of endometriosis care is not “surgery versus no surgery”. It is a precision model that treats anatomy, nerves, central sensitization, autonomic dysfunction, and the whole neuroimmune context of pelvic pain.

The most interesting future is not one in which psychedelics replace surgery. It is one in which pelvic pain care becomes more precise.

• The patient with active ovarian disease and distorted anatomy may need surgery.

• The patient with residual burning pain after surgery may need nerve-directed evaluation.

• The patient with widespread pain and autonomic dysregulation may need a broader neuroimmune strategy.

• In time, selected patients with entrenched sensitization-dominant pain may become candidates for carefully studied neuroplasticity-based therapies, including psychedelic-assisted interventions or other vagus- and brain-body-modulating approaches.

That future is worth exploring – but only with rigor.

Dr. Vidali’s Commentary

“Psychedelics are interesting not because they solve endometriosis, but because they may eventually help us treat a subset of patients whose pain has become deeply embedded in the nervous system. In endometriosis, that means we have to think beyond lesions alone. We have to think neurocentric: nerves, central sensitization, fibromyalgia overlap, autonomic dysfunction, and perhaps even vagal pathways. But the science has to lead. These therapies are not approved treatments for endometriosis pain, and they should never become an excuse to ignore the underlying disease.”

Selected References

• Reuters. Trump signs order to accelerate access to psychedelic drug treatments. April 18, 2026.

• The White House. Fact Sheet: President Donald J. Trump is Accelerating Medical Treatments for Serious Mental Illness. April 18, 2026.

• U.S. Food and Drug Administration. Accelerated Approval Program. Updated February 27, 2026.

• American College of Obstetricians and Gynecologists. Chronic Pelvic Pain. Practice Bulletin No. 218. 2020.

• Gentles A, et al. Nociplastic Pain in Endometriosis: A Scoping Review. 2024.

• Aday JS, et al. Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. Frontiers in Pain Research. 2025.

• Veeva clinical trial registry. Psilocybin for Chronic Pelvic Pain in Women: A Pilot Feasibility Study. Accessed April 18, 2026.